Mevion Medical Systems Delivers First MEVION S250 Proton Therapy System for Treatment
TechPrecision Corporation, an industry leading global manufacturer of precision, large-scale fabricated and machined metal components and tested systems with customers in the naval/maritime, energy and precision industrial sectors, today congratulated Mevion Medical Systems on the milestone event of delivering the world's first MEVION S250 Proton Therapy System for treatment at the S. Lee Kling Proton Therapy Center at Barnes-Jewish Hospital in St. Louis. A patient with a rare type of cancer called chondrosarcoma at the base of the skull has become the first person in the world to receive proton therapy using the system.
The MEVION S250 is a unique proton therapy device designed to deliver highly precise doses of radiation while limiting unnecessary radiation to healthy tissue. TechPrecision has partnered with Mevion Systems since 2006 helping to develop for the innovative, low cost and smaller proton beam radiotherapy solution for treating tumors. In January 2013, TechPrecision announced a five-year agreement with Mevion to exclusively produce precision components for their proton beam radiotherapy system.
"This is a critical next step to continuing the rollout of this innovative, cost-effective and precise device which promises to greatly improve the treatment of specific types of cancers," commented Len Anthony, TechPrecision's Executive Chairman. "We are proud of the part TechPrecision has played in delivering this strategic project which will greatly benefit patients and which has been eagerly awaited by the medical community, reflected in the current 11 systems under active development in the U.S. alone. Previously, proton therapy adoption was limited by the high costs of larger conventional systems, but the MEVION S250 system offers significantly lower capital and operating costs, enabling a wider range of facilities to provide proton therapy."